EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Glucagon‐Like Peptide‐1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality‐of‐Life Outcomes

Eman Almukhadeb, Khalid Nabil Nagshabandi iD, Naif Alshehri, Khalid Alosaimi iD, Hala Abdullah Almusa, Almuntsrbellah Almudimeegh

International Journal of Dermatology · 2026-06 · 65 (6) · 1168-1175

DOI: 10.1111/ijd.70346 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Dermatology, online erschienen am 23.02.2026. Verfasst von Eman Almukhadeb und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Overweight. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease closely associated with obesity and metabolic dysfunction, which contribute to increased disease severity, reduced treatment response, and impaired quality of life. Incretin‐based therapies, including glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonists, are increasingly used for obesity and metabolic disease, prompting interest in their potential adjunctive role in HS management. To synthesize the available human evidence on the use of incretin‐based therapies in patients with HS, focusing on clinical outcomes, weight change, and patient‐reported measures. A narrative review of the published literature was conducted using major medical databases. Eligible publications included case reports, case series, and observational studies reporting HS outcomes in patients treated with GLP‐1 RAs or dual GIP/GLP‐1 receptor agonists. Findings were summarized descriptively and interpreted in the context of metabolic modulation. The current evidence base consists predominantly of case‐level reports and a limited number of observational cohorts. Across studies, incretin‐based therapies were associated with significant weight loss and concurrent improvements in HS disease activity, flare frequency, pain, and quality of life. Improvements in HS outcomes generally paralleled weight reduction, suggesting that metabolic effects play a primary role. Evidence supporting weight‐independent anti‐inflammatory effects remains limited and inconclusive. Incretin‐based therapies appear to offer potential benefit as metabolic adjuncts in HS, particularly for patients with coexisting obesity or metabolic syndrome. However, available data are observational and hypothesis‐generating. Prospective controlled studies are required to clarify mechanisms, identify optimal patient populations, and define the role of incretin‐based therapies within comprehensive HS management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaGlucagon-Like Peptide-1 Receptor AgonistsObesityOverweightMetabolic SyndromeQuality of LifeHumansObservational Studies as TopicSymptom Flare UpPatient Reported Outcome MeasuresWeight LossTreatment OutcomeReceptors, Gastrointestinal Hormone

Stichwörter der Autor:innen

acne inversaglucagon‐like peptide‐1 receptor agonisthidradenitis suppurativaliraglutideobesitypatient‐reported outcomessemaglutidetirzepatide

Substanzen

Glucagon-Like Peptide-1 Receptor Agonistsgastric inhibitory polypeptide receptorReceptors, Gastrointestinal Hormone

Autor:innen und Institutionen

  • Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
  • Division of Plastic Surgery, Department of Surgery, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs (MNG-HA), King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia.
  • Department of Dermatology and Allergy, Clinical Research Center for Hair and Skin Science, Charité-Universitätsmedizin, Berlin, Germany.

ORCID-Profile: Khalid Nabil Nagshabandi, Khalid Alosaimi

Zitieren

APA

Almukhadeb, E., Nagshabandi, K. N., Alshehri, N., Alosaimi, K., Almusa, H. A., & Almudimeegh, A. (2026). Glucagon‐Like Peptide‐1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality‐of‐Life Outcomes. International Journal of Dermatology, 65(6), 1168-1175. https://doi.org/10.1111/ijd.70346

Vancouver

Almukhadeb E, Nagshabandi KN, Alshehri N, Alosaimi K, Almusa HA, Almudimeegh A. Glucagon‐Like Peptide‐1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality‐of‐Life Outcomes. International Journal of Dermatology. 2026;65(6):1168-1175. doi:10.1111/ijd.70346

BibTeX
@article{Almukhadeb2026,
  author = {Almukhadeb, Eman and Nagshabandi, Khalid Nabil and Alshehri, Naif and Alosaimi, Khalid and Almusa, Hala Abdullah and Almudimeegh, Almuntsrbellah},
  title = {Glucagon‐Like Peptide‐1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality‐of‐Life Outcomes},
  journal = {International Journal of Dermatology},
  year = {2026},
  volume = {65},
  number = {6},
  pages = {1168--1175},
  doi = {10.1111/ijd.70346}
}
Kostenlos starten →